NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $10.98 -0.21 (-1.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.93▼$11.3550-Day Range$7.65▼$11.6652-Week Range$2.55▼$11.90Volume593,931 shsAverage Volume879,068 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$18.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ARS Pharmaceuticals alerts: Email Address ARS Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.0% Upside$18.33 Price TargetShort InterestBearish18.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 6 Articles This WeekInsider TradingSelling Shares$4.86 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.65) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector544th out of 936 stocksPharmaceutical Preparations Industry246th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.37% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 27.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRY. Previous Next 3.0 News and Social Media Coverage News SentimentARS Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest8 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows6 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,856,040.00 in company stock.Percentage Held by Insiders40.10% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About ARS Pharmaceuticals Stock (NASDAQ:SPRY)ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More SPRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRY Stock News HeadlinesJuly 19, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells $1,140,000.00 in StockJuly 12, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 SharesJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 27 at 6:00 AM | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up to $10.40July 26 at 7:28 AM | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Raymond JamesJuly 20, 2024 | americanbankingnews.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 100,000 Shares of StockJune 28, 2024 | globenewswire.comARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)June 25, 2024 | seekingalpha.comARS Pharmaceuticals On Track With Neffy Despite Regulatory HurdlesJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...May 11, 2024 | finance.yahoo.comARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)May 9, 2024 | investorplace.comSPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024May 9, 2024 | globenewswire.comARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | nasdaq.comARS Pharmaceuticals, Inc. Common Stock (SPRY) Insider ActivityApril 30, 2024 | finance.yahoo.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 30, 2024 | globenewswire.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 26, 2024 | msn.comInsider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679KApril 19, 2024 | investing.comArs Pharmaceuticals CEO sells over $928k in company stockSee More Headlines Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRY CUSIPN/A CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$18.33 High Stock Price Target$19.00 Low Stock Price Target$18.00 Potential Upside/Downside+67.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-496,960.06% Return on Equity-21.14% Return on Assets-20.53% Debt Debt-to-Equity RatioN/A Current Ratio60.90 Quick Ratio60.90 Sales & Book Value Annual Sales$30,000.00 Price / Sales35,461.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book4.58Miscellaneous Outstanding Shares96,890,000Free Float58,040,000Market Cap$1.06 billion OptionableOptionable Beta0.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Richard Lowenthal M.B.A. (Age 58)M.S., MSMSEL, Founder, President, CEO & Director Comp: $2.75MDr. Sarina Tanimoto M.B.A. (Age 55)M.D., Co-Founder & Chief Medical Officer Comp: $2.47MMr. Alexander A. Fitzpatrick Esq. (Age 57)Chief Legal Officer & Secretary Comp: $677.14kDr. Robert Bell Ph.D.Co-Founder & Chief Science OfficerMs. Kathleen D. Scott CPAChief Financial OfficerMr. Brian T. Dorsey M.S. (Age 55)Chief Operations Officer Mr. Daniel RelovskySenior Vice President of MarketingMr. Harris Kaplan M.B.A. (Age 72)Executive Vice President of Commercial Strategy Mr. Eric Karas (Age 51)Chief Commercial Officer Comp: $618.61kMr. Justin Chakma (Age 34)Chief Business Officer & Secretary More ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNPerrigoNYSE:PRGOUltragenyx PharmaceuticalNASDAQ:RARECorcept TherapeuticsNASDAQ:CORTArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 69,394 shares on 7/26/2024Ownership: 0.144%Richard E LowenthalSold 100,000 sharesTotal: $1.14 M ($11.40/share)Wealth Enhancement Advisory Services LLCSold 10,994 shares on 7/16/2024Ownership: 0.055%SG Americas Securities LLCBought 99,986 shares on 7/12/2024Ownership: 0.115%Sarina TanimotoSold 100,000 sharesTotal: $962,000.00 ($9.62/share)View All Insider TransactionsView All Institutional Transactions SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $5.48 at the start of the year. Since then, SPRY stock has increased by 100.4% and is now trading at $10.98. View the best growth stocks for 2024 here. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Who are ARS Pharmaceuticals' major shareholders? Top institutional investors of ARS Pharmaceuticals include Bank of New York Mellon Corp (0.14%), SG Americas Securities LLC (0.12%) and Wealth Enhancement Advisory Services LLC (0.05%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver and Kathleen D Scott. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
